The approval of the first small interfering RNA (siRNA) drug Patisiran by FDA in 2018 marks
a new era of RNA interference (RNAi) therapeutics. MicroRNAs (miRNA), an important post …

Discoveries in the past decade have highlighted the potential of mRNA as a therapeutic
target for cancer. Specifically, RNA sequencing revealed that, in addition to gene mutations …

Alternative cleavage and polyadenylation (APA) is a widespread mechanism to generate
mRNA isoforms with alternative 3′ untranslated regions (UTRs). The expression of …

Abstract The p21-Activated kinase 1 (PAK1), a member of serine-threonine kinases family,
was initially identified as an interactor of the Rho GTPases RAC1 and CDC42, which affect a …

Alternative polyadenylation (APA) is a molecular process that generates diversity at the 3′
end of RNA polymerase II transcripts from over 60% of human genes. APA is derived from …

Occurring in over 60% of human genes, alternative polyadenylation (APA) results in
numerous transcripts with differing 3'ends, thus greatly expanding the diversity of mRNAs …

A crucial feature of gene expression involves RNA processing to produce 3′ ends through
a process termed 3′ end cleavage and polyadenylation (CPA). This ensures the nascent …

Alternative polyadenylation (APA) is a gene regulatory process that dictates mRNA 3′-UTR
length, resulting in changes in mRNA stability and localization. APA is frequently disrupted …

The mammalian cleavage factor I subunit CFIm25 (NUDT21) binds to the UGUA sequences
of precursor RNAs. Traditionally, CFIm25 is known to facilitate 3′ end formation of pre …

This paper concerns 3′-untranslated regions (3′ UTRs) of mRNAs, which are non-coding
regulatory platforms that control stability, fate and the correct spatiotemporal translation of …